Systemic Sclerosis (Scleroderma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Systemic Sclerosis (Scleroderma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis (Scleroderma) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Systemic Sclerosis (Scleroderma) (Immunology) pipeline landscape.

Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pains, joint pain and swelling, ulcers occurring on fingertips, bloating of the tummy and diarrhea or constipation. Treatment includes antibiotic, pain relievers and immunosuppressant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Sclerosis (Scleroderma) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 23, 15, 1, 2, 42 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma) (Immunology).
• The pipeline guide reviews pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Systemic Sclerosis (Scleroderma) (Immunology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Systemic Sclerosis (Scleroderma) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology)

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) (Immunology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned
Companies Mentioned

A. Menarini Industrie Farmaceutiche Riunite Srl
Acceleron Pharma Inc
Accuitis Pharmaceuticals Inc
AKL Research and Development Ltd
Allysta Pharmaceuticals Inc
Amgen Inc
AnaMar AB
Annji Pharmaceutical Co Ltd
APIE Therapeutics Inc
arGentis Pharmaceuticals LLC
Aryogen Pharmed Co
AstraZeneca Plc
Atlantic Healthcare Plc
Aurora Research Institute LLC
Avotres Inc
Beijing Toll Biotech Co Ltd
Biogen Inc
Biomendics LLC
Blade Therapeutics Inc
BriaCell Therapeutics Corp
Bristol-Myers Squibb Co
Cantargia AB
Castle Creek Biosciences Inc
Celdara Medical LLC
Centessa Pharmaceuticals Plc
Certa Therapeutics Pty Ltd
Chemomab Therapeutics Ltd
Chugai Pharmaceutical Co Ltd
Civi Biopharma Inc
CohBar Inc
Corbus Pharmaceuticals Inc
Coya Therapeutics Inc
CSL Ltd
Cumberland Pharmaceuticals Inc
Cureveda LLC
D&D Pharmatech Co Ltd
Daewoong Pharmaceutical Co Ltd
Emerald Health Sciences Inc
FibroBiologics LLC
Foresee Pharmaceuticals Co Ltd
Fresenius Kabi SwissBioSim GmbH
Galapagos NV
Galecto Inc
Genentech USA Inc
GenKyoTex SA
Genmab AS
Genrix (Shanghai) Biopharmaceutical Co Ltd
Gesynta Pharma AB
Gilead Sciences Inc
GlaxoSmithKline Plc
GNI Group Ltd
Horizon Therapeutics Plc
iBio Inc
Ichnos Sciences Inc
Iltoo Pharma
ImmuneMed Inc
Johnson & Johnson
Kadmon Holdings Inc
Leadiant Biosciences Inc
LightOx Ltd
Link Genomics Inc
Luminary Therapeutics Inc
Mallinckrodt Plc
MDI Therapeutics Inc
Mitsubishi Tanabe Pharma Corp
Ono Pharmaceutical Co Ltd
Opsidio LLC
Panorama Researchama Research
Patagonia Pharmaceuticals LLC
PDX Pharmaceuticals LLC
Peptinov SAS
Pfizer Inc
Prometheus Biosciences Inc
RadBio
Recursion Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Resolys Bio Inc
Ribomic Inc
Riptide Bioscience Inc
Seagen Inc
Shanghai YaKe Biotechnology Co Ltd
Signablok Inc
Takeda Pharmaceutical Co Ltd
Talaris Therapeutics Inc
Thirona Bio Inc
Timber Pharmaceuticals Inc
TRACON Pharmaceuticals Inc
Tvardi Therapeutics Inc
Unity Biotechnology Inc
Vicore Pharma AB
Welichem Biotech Inc